4.7 Article

Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Pharmacology & Pharmacy

Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect

Frank Schneider et al.

Summary: Deutetrabenazine is a deuterated form of tetrabenazine approved for treating chorea in Huntington's disease and tardive dyskinesia. Studies show that deutetrabenazine has longer half-lives and lower peak-to-trough fluctuations for active metabolites in comparison to tetrabenazine.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2021)

Article Chemistry, Medicinal

Assessing Vesicular Monoamine Transport and Toxicity Using Fluorescent False Neurotransmitters

Carlie A. Black et al.

Summary: The study developed an assay using a fluorescent false neurotransmitter to visualize alterations in dopamine vesicular packaging. Environmental toxicants showed minor impact on vesicular packaging, suggesting they are weak inhibitors of VMAT2 activity in vitro.

CHEMICAL RESEARCH IN TOXICOLOGY (2021)

Article Clinical Neurology

Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia

Benjamin J. Dorfman et al.

Summary: Deutetrabenazine is effective in reducing dyskinesia in TD, but ongoing studies are exploring drug selection and cost-effectiveness among existing VMAT2 inhibitors. Other areas of investigation include novel anti-dyskinetic agents and the use of deep brain stimulation.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2021)

Review Neurosciences

Dynamic control of the dopamine transporter in neurotransmission and homeostasis

Mengfei Bu et al.

Summary: The dopamine transporter (DAT) plays a crucial role in regulating dopamine neurotransmission and is implicated in neurodegenerative diseases like Parkinson's. Surface expression of DAT is dynamically regulated through endocytic trafficking, impacting dopamine signaling. Research shows that dysregulation of DAT trafficking is linked to neurodegenerative diseases.

NPJ PARKINSONS DISEASE (2021)

Review Pharmacology & Pharmacy

Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia

Farah Khorassani et al.

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2020)

Article Clinical Neurology

Treatment of Tardive Dyskinesia

Hassaan H. Bashir et al.

NEUROLOGIC CLINICS (2020)

Review Neurosciences

Recent Advances in the Pharmacology of Tardive Dyskinesia

Stanley N. Caroff

CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE (2020)

Editorial Material Biochemistry & Molecular Biology

Classics in Neuroimaging: Radioligands for the Vesicular Monoamine Transporter 2

Michael R. Kilbourn et al.

ACS CHEMICAL NEUROSCIENCE (2019)

Review Clinical Neurology

Valbenazine for the treatment of tardive dyskinesia

Thomas Mueller

EXPERT REVIEW OF NEUROTHERAPEUTICS (2017)

Review Clinical Neurology

Pharmacological treatment of tardive dyskinesia: recent developments

Stanley N. Caroff et al.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2017)

Review Clinical Neurology

Valbenazine for the treatment of tardive dyskinesia

Thomas Mueller

EXPERT REVIEW OF NEUROTHERAPEUTICS (2017)

Review Clinical Neurology

Pharmacological treatment of tardive dyskinesia: recent developments

Stanley N. Caroff et al.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2017)

Editorial Material Psychiatry

A Biopsychosocial Approach to Improving Quality of Life in Tardive Dystonia

Charlotte Buscombe et al.

JOURNAL OF PSYCHIATRIC PRACTICE (2010)